Here are relevant reports on : parkinsons-disease-market
-
Injectable Pharma Packaging Market by Type (Prefilled Syringes, Vials, Ampoules, Cartridges), Packaging Type (Primary, Secondary), Application (Chronic Disease Management, Vaccines, Biologics, Insulin, Oncology), and Region-Global Forecast to 2030
Injectable Pharma Packaging Market is projected to reach USD 98.8 billion by 2030 from USD 44.8 billion in 2025, at a CAGR of 17.5% during the forecast period. The key players in the injectable pharma packaging market include Schott AG (Germany), Gerresheimer AG (Germany), West Pharmaceutical Services (US), Stevanato Group (Italy), BD (Becton, Dickinson and Company) (US), SGD Pharma (France), Nipro Corporation (Japan), AptarGroup (US), Catalent, Inc. (US), and Datwyler Group (Switzerland).
- Published: June 2026
- Price: $ 4950
- TOC Available:
-
Parkinson's Disease Treatment Market by Drug Class (Carbidopa/Levodopa, Dopamine Receptor Agonists, MAO-Inhibitors), Distribution Channel (Hospital, Online, Retail Pharmacies), Patient Care Setting (Hospitals, Clinics) - Global Forecast to 2022
The Parkinson's disease treatment market is expected to reach USD 5.69 Billion by 2022 from USD 4.24 Billion in 2017, at a CAGR of 6.1%. The market is being driven by the growth in aging population and the associated increase in the prevalence of Parkinson’s disease and government funding for research. Some of the major players operating in the Parkinson’s disease treatment market include Teva (Israel), Novartis AG (Switzerland), GSK (UK), AbbVie (US), Merck (US), Boehringer Ingelheim (Germany), Impax Laboratories (US), Lundbeck (Denmark), Sun Pharma (India), Wockhardt (India), UCB (Belgium), Valeant Pharmaceuticals (Canada), and Acadia (US).
- Published: October 2017
- Price: $ 4950
- TOC Available:
-
Genomic Biomarkers Market by Product & Service (Consumable, Software), Type (Safety, Efficacy), Technology (NGS, PCR), Disease (Cancer, Infectious) -Forecast to 2030
The global genomic biomarkers market, valued at US$26.78 billion in 2024, stood at US$29.00 billion in 2025 and is projected to advance at a resilient CAGR of 11.6% from 2024 to 2030, culminating in a forecasted valuation of US$50.31 billion by the end of the period. Genomic biomarkers are measurable features of DNA and RNA used to aid disease diagnosis, characterize disease states, and guide therapeutic decision-making.
- Published: June 2026
- Price: $ 4950
- TOC Available:
-
Biosimulation Market by Phase (Drug Discovery, Preclinical, Regulatory), Modality (Antibody, Peptide), Application (Molecular Design, PK/PD, QSP, Trial Simulation, Disease Modeling), Indication (Cardio, Onco), End User (CRO, Pharma) – Global Forecast to 2031
The global biosimulation market is projected to reach USD 9.24 billion by 2031, growing at a CAGR of 16.7% during the forecast period (2026–2031). The report covers key segments, regional analysis, and competitive landscape across the market ecosystem.
- Published: June 2026
- Price: $ 4950
- TOC Available:
-
Precision Nutrition Market by Technology (Metabolomics, Genomics, Transcriptomics, Proteomics), Application (Disease Management, General Health & Wellness, Weight Management), Service Type, End-Use, Supplement, and Region - Global Forecast to 2029
The market for precision nutrition is projected to reach USD 12.89 billion by 2029, at a CAGR of 16.2% during the forecast period. The report profiles key players such as Viome Life Sciences, Inc. (US), Prenetics Global Limited (China), ZOE Limited (UK), myDNA Life Australia Pty Ltd. (Australia) , 23andMe, Inc. (US), DayTwo Inc (US), Nutrigenomix (Canada), Genesis Healthcare Co. (Japan), AMILI (Singapore), and SelfDecode (US).
- Published: November 2024
- Price: $ 4950
- TOC Available:
-
Digital Pathology Market by Product (Brightfield Scanner, Enterprise Software, Storage System), Application (Teleconsultation, Disease Diagnosis, Drug Discovery), Indication (Onco, Hemo), End User (Pharma & Biotech, Hospital) Al- Global Forecast to 2031
The global digital pathology market is projected to reach USD 2.86 billion by 2031, growing at a CAGR of 12.5% during the forecast period (2026–2031). The report covers key segments, regional analysis, and competitive landscape across the market ecosystem.
- Published: June 2026
- Price: $ 4950
- TOC Available:
-
Veterinary Biologics Market by Product (Monoclonal Antibodies, Diagnostic Kits, Immunoglobulins & Antitoxins), RoA (Injectable, Oral), Application (Infectious Disease Prevention, Dermatology, Pain Management), Animal, End User - Global Forecast to 2030
The global veterinary biologics market, valued at US$2.61 billion in 2024, stood at US$2.72 billion in 2025 and is projected to advance at a resilient CAGR of 5.2% from 2024 to 2030, culminating in a forecasted valuation of US$3.51 billion by the end of the period. The market growth is fueled by increasing demand for effective animal therapeutics, rising populations of livestock and companion animals, and greater awareness of animal health and disease prevention.
- Published: October 2025
- Price: $ 4950
- TOC Available:
-
Asia Pacific Human Microbiome Market by Drug & Supplement (Drugs, Probiotics, Prebiotics), Disease (Infectious, Gastrointestinal, Endocrine & Metabolic Diseases), Type (BCT/FMT, LBP), End User (Hospitals, Clinics, Long-term Care) - Forecast to 2031
The Asia Pacific Human Microbiome Market, valued at US$0.19 billion in 2024, stood at US$0.26 billion in 2025 and is projected to advance at a resilient CAGR of 31.0% from 2025 to 2031, culminating in a forecasted valuation of US$1.31 billion by the end of the period. Market growth is driven by an increasing focus on preventive and personalized health, rising adoption of microbiome-based diagnostics and therapeutic solutions, and rapid advances in next-generation sequencing, AI-enabled microbiome analytics, and regional bioinformatics capabilities.
- Published: June 2026
- Price: $ 4950
- TOC Available:
-
Tissue Diagnostics Market by Product (Consumables [Antibodies, Kits, Reagents, Probes], Instruments [Systems, Scanner], Software, Services), Technology (ISH, IHC, Slide Staining), Disease Type (Breast Cancer, Lymphoma, Prostate Cancer) - Global Forecast to 2030
The global Tissue Diagnostics market, valued at USD 6.19 billion in 2024, stood at USD 6.74 billion in 2025 and is projected to advance at a resilient CAGR of 10.0% from 2025 to 2030, culminating in a forecasted valuation of USD10.86 billion by the end of the period. The market growth is driven by the rising incidence of cancer and the growing demand for digital pathology, which are fueling the need for more accurate and high-throughput tissue-based diagnostics.
- Published: February 2026
- Price: $ 4950
- TOC Available:
-
Transdermal Pharmaceutical Packaging Market by Type (Patches, Gels), Material (Plastic, Glass, Metal), Application (Chronic Disease Management, Pain Management, Hormone Replacement Therapy), and Region – Global Forecast to 2030
The transdermal pharmaceutical packaging market is projected to grow from USD 4.05 billion in 2025 to USD 8.13 billion by 2030, at a CAGR of 15.0%. The key players in the transdermal pharma packaging market include 3M Company (US), Hisamitsu Pharmaceutical (Japan), Novartis (Switzerland), Teva Pharmaceutical Industries (Israel), Johnson & Johnson (US), Bayer (Germany), GlaxoSmithKline (UK), LTS Lohmann Therapie-Systeme (Germany), Noven Pharmaceuticals (US), and Nitto Denko (Japan).
- Published: June 2026
- Price: $ 4950
- TOC Available:
Records 41 to 50 of 50
